Form 4: Definitive Healthcare Chief Legal Officer Awarded Significant RSU Grant

Jonathan Paris, Chief Legal Officer of Definitive Healthcare Corp., has been granted 421,349 restricted stock units, aligning his interests with long-term company performance.

Summary

• Jonathan Paris, the Chief Legal Officer of Definitive Healthcare Corp. (DH), was granted 421,349 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on July 1, 2025.
• These RSUs represent a contingent right to receive one share of the Issuer's Class A Common Stock for each unit.
• The vesting schedule for these RSUs is structured with 25% vesting on July 1, 2026.
• Following the initial vesting, 6.25% of the RSUs will vest every three months thereafter over the subsequent three years.
• The vesting is contingent upon Mr. Paris's continued service with Definitive Healthcare Corp. through each respective vesting date.

Sentiment

Score: 7

Explanation: The RSU grant is a positive signal for executive retention and alignment with shareholder interests, indicating stability in leadership. It does not, however, directly impact immediate financial performance or introduce new risks beyond standard compensation practices.

Positives

• The grant of Restricted Stock Units to the Chief Legal Officer aligns his long-term financial interests with the company's performance and shareholder value.
• This RSU award serves as a strong retention mechanism for a key executive, ensuring continuity in leadership and strategic direction.

Risks

• The RSUs are subject to forfeiture if the Reporting Person's service with the Issuer ceases before the vesting dates.

Future Outlook

The structured vesting schedule of the RSUs indicates an expectation of continued service from the Chief Legal Officer for at least the next three years, reinforcing stability in the company's legal leadership.

Industry Context

The granting of Restricted Stock Units (RSUs) is a common practice in the technology and healthcare technology sectors for executive compensation, aiming to attract, retain, and incentivize key talent by aligning their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• RSU grants are a standard component of executive compensation packages across various industries, including healthcare technology.
• The specific size of the grant (421,349 units) for a Chief Legal Officer is substantial, reflecting a significant commitment to the executive.
• The document does not provide specific comparable companies, projects, or results to benchmark the size or terms of this RSU grant against direct industry peers.

Management Changes

Related Party Transactions

• The grant of 421,349 Restricted Stock Units to Jonathan Paris, the Chief Legal Officer, constitutes a related party transaction as it is a compensation arrangement between the company and a key executive.

Stakeholder Impact

• Shareholders: Benefits from the alignment of executive interests with long-term company performance and enhanced executive retention.
• Employees: May view the grant as a sign of stability and commitment from senior leadership.
• Management: The grant serves as a significant incentive and retention tool for the Chief Legal Officer.

Next Steps

• Vesting of 25% of the RSUs on July 1, 2026.
• Subsequent vesting of 6.25% of the RSUs every three months over the following three years, subject to continued service.

Key Dates

Recommendation

Keywords

Definitive Healthcare, DH, Jonathan Paris, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, SEC Form 4, Corporate Governance